Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
As one of the world’s leading killer diseases, AIDS, along with its accompanying infectious microorganism, HIV, has proven to be extremely difficult to cure. However, a recent development in one of the AIDS/HIV cure tests might finally put an end to this dry spell. The vaccine has been proven safe enough to make it to the next stage of human trials.
This study is being conducted by Harvard researchers, who published their findings in The Lancet recently. Dr. Dan H. Barouch is one of the co-authors and principal investigators of the study, and he expressed cautious optimism about the results of their research. As a Harvard Medical School professor of medicine and the Center for Virology and Vaccine Research director, his opinion on such matters certainly has weight.
"I would say that we are pleased with these data so far, but we have to interpret the data cautiously," Dr. Barouch said. "We have to acknowledge that developing an HIV vaccine is an unprecedented challenge, and we will not know for sure whether this vaccine will protect humans."
As CNN notes, this development does not necessarily mean that the AIDS/HIV cure has been proven unequivocally effective. Rather, it has simply been proven to be safe enough to be tested on an even bigger batch of human subjects.
Reporting on developments like these is always a juggling feat, where the importance of progress needs to be tempered with the sobering facts. While it’s encouraging that HIV vaccine research is progressing, the next stage in human trials could prove that this particular cure is still ineffective. There have only been five vaccine concepts that have reached this point in over 35 years after all.
The trials are already underway right now with over 2,600 female test subjects in Africa. The ultimate goal is to find out whether this particular AIDS/HIV cure can actually provide protection to humans. So far, the best results that the researchers have gotten are traces of HIV antibodies in the subjects. This is not enough to provide concrete evidence that it works.
